Deutsche Bank AG grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 27.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,287 shares of the biotechnology company’s stock after buying an additional 25,782 shares during the quarter. Deutsche Bank AG owned 0.29% of Ascendis Pharma A/S worth $7,535,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 12.7% in the 4th quarter. Geode Capital Management LLC now owns 30,743 shares of the biotechnology company’s stock worth $1,926,000 after acquiring an additional 3,459 shares in the last quarter. FMR LLC grew its position in Ascendis Pharma A/S by 1.2% during the fourth quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock valued at $263,333,000 after buying an additional 50,984 shares during the period. Squarepoint Ops LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at about $204,000. D. E. Shaw & Co. Inc. grew its position in Ascendis Pharma A/S by 14.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 46,181 shares of the biotechnology company’s stock valued at $2,893,000 after buying an additional 5,881 shares during the period. Finally, Partner Fund Management L.P. bought a new position in Ascendis Pharma A/S during the fourth quarter valued at about $1,724,000. Institutional investors own 95.46% of the company’s stock.

Shares of NASDAQ:ASND opened at $107.75 on Friday. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of -28.81 and a beta of 1.01. Ascendis Pharma A/S has a twelve month low of $53.21 and a twelve month high of $131.76.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.30. The firm had revenue of $12.00 million during the quarter. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. On average, sell-side analysts expect that Ascendis Pharma A/S will post -3.93 EPS for the current fiscal year.

Several equities analysts recently weighed in on ASND shares. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research report on Friday, January 18th. Wedbush set a $217.00 price target on shares of Ascendis Pharma A/S and gave the company an “outperform” rating in a research report on Thursday, March 7th. Evercore ISI started coverage on shares of Ascendis Pharma A/S in a research report on Monday, March 25th. They set an “outperform” rating for the company. BidaskClub upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Finally, Credit Suisse Group reduced their price target on shares of Ascendis Pharma A/S from $151.00 to $139.00 and set an “outperform” rating for the company in a research report on Friday, March 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $135.56.

ILLEGAL ACTIVITY WARNING: “Deutsche Bank AG Has $7.54 Million Stake in Ascendis Pharma A/S (ASND)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2019/04/21/deutsche-bank-ag-has-7-54-million-stake-in-ascendis-pharma-a-s-asnd.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: Asset Allocation and Your Retirement

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.